Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:FUSNNASDAQ:KRYSNASDAQ:PCVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$19.47-2.1%$20.34$8.91▼$25.67$4.63B0.573.72 million shs4.18 million shsFUSNFusion Pharmaceuticals$21.55$21.50$2.31▼$21.60$1.83B-0.691.69 million shsN/AKRYSKrystal Biotech$131.39-2.3%$169.86$127.90▼$219.34$3.80B0.79302,269 shs427,870 shsPCVXVaxcyte$29.42-2.1%$44.91$27.66▼$121.06$3.80B1.271.33 million shs2.14 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics-2.79%-14.11%+2.47%+25.51%+126.17%FUSNFusion Pharmaceuticals0.00%0.00%0.00%0.00%+0.56%KRYSKrystal Biotech-3.51%-3.54%-18.47%-11.10%-13.11%PCVXVaxcyte-4.87%+2.77%-3.69%-64.82%-54.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.9784 of 5 stars2.64.00.00.03.21.71.9FUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKRYSKrystal Biotech4.8786 of 5 stars4.52.00.04.72.83.31.9PCVXVaxcyte3.1251 of 5 stars4.62.00.00.02.82.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2524.55% UpsideFUSNFusion Pharmaceuticals 0.00N/AN/AN/AKRYSKrystal Biotech 3.00Buy$218.6366.39% UpsidePCVXVaxcyte 3.10Buy$136.50363.97% UpsideCurrent Analyst Ratings BreakdownLatest FUSN, ADMA, PCVX, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/7/2025KRYSKrystal BiotechGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$195.00 ➝ $189.005/7/2025KRYSKrystal BiotechChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$219.00 ➝ $219.005/6/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.00 ➝ $240.004/28/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$221.00 ➝ $240.004/22/2025PCVXVaxcyteCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight4/8/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$90.00 ➝ $90.004/1/2025PCVXVaxcyteThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$138.00 ➝ $100.004/1/2025PCVXVaxcyteBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$157.00 ➝ $137.004/1/2025PCVXVaxcyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $90.003/31/2025PCVXVaxcyteEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.07$0.06 per share311.70$0.60 per share32.45FUSNFusion Pharmaceuticals$2.07M885.53N/AN/A$3.07 per share7.02KRYSKrystal Biotech$333.45M11.39$3.34 per share39.38$32.85 per share4.00PCVXVaxcyteN/AN/AN/AN/A$13.04 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8569.5428.22N/A17.80%53.20%26.07%N/AFUSNFusion Pharmaceuticals-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/AKRYSKrystal Biotech$10.93M$4.1643.9413.03N/A30.69%11.41%10.40%N/APCVXVaxcyte-$402.27M-$3.99N/AN/AN/AN/A-23.53%-22.20%5/14/2025 (Estimated)Latest FUSN, ADMA, PCVX, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PCVXVaxcyte-$1.02-$1.04-$0.02-$1.04N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 million2/25/2025Q4 2024PCVXVaxcyte-$1.16-$1.02+$0.14-$1.02N/AN/A2/24/2025Q4 2024KRYSKrystal Biotech$1.29$1.52+$0.23$1.52$91.35 million$91.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26FUSNFusion Pharmaceuticals0.2110.6410.64KRYSKrystal BiotechN/A7.287.76PCVXVaxcyteN/A17.8817.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%FUSNFusion Pharmaceuticals72.85%KRYSKrystal Biotech86.29%PCVXVaxcyte96.78%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%FUSNFusion Pharmaceuticals7.75%KRYSKrystal Biotech13.70%PCVXVaxcyte3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530237.62 million227.64 millionOptionableFUSNFusion Pharmaceuticals10185.06 million78.47 millionOptionableKRYSKrystal Biotech21028.90 million24.71 millionOptionablePCVXVaxcyte160129.00 million120.77 millionOptionableFUSN, ADMA, PCVX, and KRYS HeadlinesRecent News About These Companies98,739 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Purchased by Hudson Bay Capital Management LPMay 14 at 5:48 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Deutsche Bank AGMay 14 at 4:58 AM | marketbeat.comBrokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) Price Target at $136.50May 14 at 1:21 AM | americanbankingnews.comJanus Henderson Group PLC Trims Position in Vaxcyte, Inc. (NASDAQ:PCVX)May 13 at 7:56 AM | marketbeat.comAmeriprise Financial Inc. Purchases 366,622 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 13 at 4:47 AM | marketbeat.comWhat is Leerink Partnrs' Forecast for Vaxcyte Q3 Earnings?May 13 at 2:41 AM | americanbankingnews.comResearch Analysts Set Expectations for Vaxcyte Q3 EarningsMay 13 at 2:40 AM | marketbeat.comEnsign Peak Advisors Inc Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)May 12 at 6:00 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by D. E. Shaw & Co. Inc.May 12 at 5:34 AM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by BrokeragesMay 12 at 2:20 AM | marketbeat.comFred Alger Management LLC Sells 720,710 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 10, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Driehaus Capital Management LLCMay 10, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.May 10, 2025 | marketbeat.comRep. Gilbert Ray Cisneros, Jr. Buys Vaxcyte, Inc. (NASDAQ:PCVX) SharesMay 10, 2025 | marketbeat.comIs Vaxcyte, Inc. (PCVX) The Best Stock That Will Bounce Back?May 9, 2025 | insidermonkey.comVaxcyte (PCVX) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comDuquesne Family Office LLC Acquires 43,300 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)May 9, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Schonfeld Strategic Advisors LLCMay 9, 2025 | marketbeat.comDimensional Fund Advisors LP Raises Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)May 9, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Stock Position Raised by Crestline Management LPMay 8, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Braidwell LPMay 8, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit2 Smart Investments to Follow Warren Buffett’s LeadBy Ryan Hasson | April 23, 2025View 2 Smart Investments to Follow Warren Buffett’s Lead3 Mid-Cap Medical Stocks Outperforming the MarketBy Ryan Hasson | May 6, 2025View 3 Mid-Cap Medical Stocks Outperforming the MarketFUSN, ADMA, PCVX, and KRYS Company DescriptionsADMA Biologics NASDAQ:ADMA$19.47 -0.41 (-2.06%) As of 04:00 PM EasternADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Fusion Pharmaceuticals NASDAQ:FUSNFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Krystal Biotech NASDAQ:KRYS$131.39 -3.14 (-2.33%) As of 04:00 PM EasternKrystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Vaxcyte NASDAQ:PCVX$29.42 -0.63 (-2.10%) As of 04:00 PM EasternVaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
